89bio, Inc. financial data

Symbol
ETNB on Nasdaq
Industry
Pharmaceutical Preparations
Location
142 Sansome Street, Second Floor, San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K % +29.3%
Debt-to-equity 12.4 % -23.2%
Return On Equity -35.4 % +11%
Return On Assets -31.5 % +8.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106M shares +40.3%
Common Stock, Shares, Outstanding 105M shares
Entity Public Float 1.18B USD +3767%
Common Stock, Value, Issued 105K USD +40%
Weighted Average Number of Shares Outstanding, Basic 99.8M shares +34.7%
Weighted Average Number of Shares Outstanding, Diluted 99.8M shares +34.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 157M USD +59.7%
General and Administrative Expense 34M USD +38.2%
Operating Income (Loss) -191M USD -55.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -171M USD -43.8%
Income Tax Expense (Benefit) 134K USD
Net Income (Loss) Attributable to Parent -175M USD -47.2%
Earnings Per Share, Basic -1.96 USD/shares -30.7%
Earnings Per Share, Diluted -1.96 USD/shares -30.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 212M USD -13.5%
Marketable Securities, Current 319M USD
Cash, Cash Equivalents, and Short-term Investments 531M USD +11.2%
Assets, Current 580M USD +17.9%
Property, Plant and Equipment, Net 27K USD -60.3%
Operating Lease, Right-of-Use Asset 1.94M USD +594%
Other Assets, Noncurrent 315K USD +9%
Assets 582M USD +18.2%
Accounts Payable, Current 17.5M USD +63%
Employee-related Liabilities, Current 3.75M USD +35.9%
Accrued Liabilities, Current 18.7M USD +24%
Liabilities, Current 41.7M USD +60.6%
Operating Lease, Liability, Noncurrent 1.46M USD +1393%
Other Liabilities, Noncurrent 3.75M USD
Liabilities 67.2M USD +33%
Accumulated Other Comprehensive Income (Loss), Net of Tax -683K USD -15%
Retained Earnings (Accumulated Deficit) -557M USD -45.7%
Stockholders' Equity Attributable to Parent 515M USD +16.5%
Liabilities and Equity 582M USD +18.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.7M USD -32%
Net Cash Provided by (Used in) Financing Activities 21M USD -93.5%
Net Cash Provided by (Used in) Investing Activities -79.9M USD -2046%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 105M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -98.6M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 212M USD -13.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 679K USD +25.3%
Deferred Tax Assets, Valuation Allowance 108M USD +42.4%
Deferred Tax Assets, Gross 109M USD +42.8%
Operating Lease, Liability 2.31M USD +553%
Depreciation 9K USD -35.7%
Payments to Acquire Property, Plant, and Equipment 6K USD +50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -175M USD -46.9%
Lessee, Operating Lease, Liability, to be Paid 2.87M USD +661%
Operating Lease, Liability, Current 759K USD +339%
Lessee, Operating Lease, Liability, to be Paid, Year Two 917K USD +396%
Lessee, Operating Lease, Liability, to be Paid, Year One 774K USD +318%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 555K USD +2313%
Lessee, Operating Lease, Liability, to be Paid, Year Three 937K USD +13286%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 12.1M USD +664%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240K USD
Additional Paid in Capital 1.07B USD
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 7K USD -72%
Deferred Tax Assets, Net of Valuation Allowance 715K USD +124%
Share-based Payment Arrangement, Expense 18.6M USD +43.6%
Operating Leases, Future Minimum Payments Due 105K USD -33.5%
Interest Expense 3.56M USD -12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%